VEGFA and liver cancer: One promising solution to overcome the intrinsic immune-evasion of liver tumors is to combine anti-VEGF agents with ICIs in liver cancers, because anti-VEGF therapies could enhance the efficacy of ICIs via the reversion of VEGF-mediated immunosuppression and promotion of T-cell infiltration in tumor microenvironment (24–26).